|
⚲
|
| Keyboard |
| Octagon Capital Advisors LP
✚
|
|
|---|---|
| CRD # | 306424 |
| SEC # | 801-118554 |
| CIK # | 0001839435 |
| AUM | 1,175.3 M (2026-03-20) |
| Employees | 10 (70% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 212-369-2829 |
| Address | 654 Madison Avenue, 21st Floor New York, NY 10065 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($M) |
|---|
| In the News | |
|---|---|
| Mon, 27 Jul 2026 | Evommune, Inc. $EVMN Stake Lessened by Octagon Capital Advisors LP — MarketBeat |
| Mon, 27 Jul 2026 | Octagon Capital Advisors LP Reduces Stock Holdings in Trevi Therapeutics, Inc. $TRVI — MarketBeat |
| Mon, 27 Jul 2026 | Abivax SA Sponsored ADR $ABVX Shares Sold by Octagon Capital Advisors LP — MarketBeat |
| Mon, 27 Jul 2026 | Octagon Capital Advisors LP Has $163.36 Million Position in Dianthus Therapeutics, Inc. $DNTH — MarketBeat |
| Mon, 27 Jul 2026 | Octagon Capital Advisors LP Sells 324,110 Shares of BridgeBio Oncology Therapeutics, Inc $BBOT — MarketBeat |
| CIK | Period |
|---|---|
| 0001839435 |
| Sector | Form 13F Holdings | Value ($M) | |
|---|---|---|---|
| Magenta Therapeutics Inc | 163.4 | ||
| UNUM Therapeutics Inc | 90.5 | ||
| Abivax Sa | 75.4 | ||
| Alumis Inc | 62.4 | ||
| MIND Medicine Mindmed Inc | 46.1 | ||
| Arrivent Biopharma Inc | 45.5 | ||
| Taysha Gene Therapies Inc | 39.6 | ||
| Kymera Therapeutics Inc | 35.4 | ||
| Mirum Pharmaceuticals Inc | 31.3 | ||
| Bioage Labs Inc | 30.6 | ||
| Xenon Pharmaceuticals Inc | 28.5 | ||
| Ocular Therapeutix Inc | 26.8 | ||
| Neuralstem Inc | 18.0 | ||
| Trevi Therapeutics Inc | 17.7 | ||
| FS Development Corp | 17.3 | ||
| Context Therapeutics Inc | 13.8 | ||
| Precision Biosciences Inc | 12.3 | ||
| DBV Technologies Sa | 12.0 | ||
| Unicycive Therapeutics Inc | 6.6 | ||
| Helix Acquisition Corp II | 6.4 | ||
| Lexeo Therapeutics Inc | 6.3 | ||
| Pharvaris NV | 4.7 | ||
| Isoray Inc | 3.3 | ||
| Evommune Inc | 3.3 | ||
| Gossamer Bio Inc | 2.5 | ||
| Prev | Page 1 | Next | |||
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| PE | Octagon Biotech Opportunities Fund I LP | [2025-03-17] | 16.5 M | 82.3 M |
| Offered $16,500,000 · Filed 2025-06-16 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $5,000,000 · Duration One year or less · Revenue Decline to Disclose | ||||
| PE | Octagon Special Opportunities Fund LP | [2022-03-21] | 5.0 M | 13.3 M |
| Offered $5,000,000 · Filed 2021-05-24 (D) · Exemption 506(b), 3(c), 3(c)(7) · Duration One year or less · Net Assets Decline to Disclose | ||||
| PE | Octagon Coinvest Opportunities Fund LP | [2021-03-18] | 29.1 M | 104.5 M |
| Offered $59,150,000 · Filed 2021-01-07 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $5,000,000 · Remaining $30,000,000 · Duration One year or less · Revenue Decline to Disclose | ||||
| HF | Octagon Investments Master Fund LP | [2019-11-08] | 709.2 M | 975.2 M |
| Filed 2025-12-05 (D/A) · Exemption 506(b), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($M) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 8 | 1,175.3 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 8 | 1,175.3 |
| By Discretionary | ||
| Discretionary | 8 | 1,175.3 |
| Non-Discretionary | 0 | 0.0 |
| Total | 8 | 1,175.3 |
| By Non-United States Persons | ||
| Non-United States Persons | 985.3 | |
| United States Persons | 190.0 | |
| Total | 8 | 1,175.3 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Jennifer Collins | Director | 232 | 47 | |
| Jonathan Morgan | Director | 50 | 12 | |
| Ting Jia | Director, Executive Officer | 16 | 2 | |
| Octagon Capital Advisors LP | Promoter | 13 | 2 | |
| Octagon Investments GP LLC | Executive Officer | 12 | 2 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001839435] | |
| SC 13G | [0001839435] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Fund Types | Hedge Fund, Private Equity |
| LEI | 549300LAL4WLS7BIZZ14 |
| Comparable Firms | State | AUM |
|---|---|---|
|
Wynkoop LLC
✚
|
CO | 1,217.3 M |
|
Hudson Cove Capital Management LLC
✚
|
NJ | 1,213.5 M |
|
Arlon Advisor LLC
✚
|
NY | 1,176.7 M |
|
Cota Capital Management LLC
✚
|
CA | 1,167.9 M |
|
Grafton Street Partners Management Company LLC
✚
|
1,163.3 M | |
|
IBEX Investors LLC
✚
|
CO | 1,160.5 M |
|
Forest Road Asset Management LLC
✚
|
CA | 1,158.5 M |
|
Corre Partners Management LLC
✚
|
NY | 1,147.8 M |
|
Winston Capital Management LLC
✚
|
VA | 1,147.2 M |
|
Ivyrock Asset Management HK Limited
✚
|
1,140.6 M |